Pancreatic Polypeptide Antibody (Rabbit mAb) [L20N2]

CatNo: F5352

Application: Reactivity: Mouse, Rat, Human

当該製品は品切れ状态で、メールアドレスをご教示いただければ、お客様に返信いたします。

代表番号: 045-509-1970|電子メール：sales@selleck.co.jp

使用情報

Dilution
IHC1:2000

Application
IHC

Source
Rabbit Monoclonal Antibody

Reactivity
Mouse, Rat, Human

Storage Buffer
PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage (from the date of receipt)
-20°C (avoid freeze-thaw cycles), 2 years

Predicted MW
10 kDa

ポジティブコントロール	Rat pancreas tissue; Mouse pancreas tissue; Human pancreas tissue
ネガティブコントロール

プロトコール

IHC
Experimental Protocol： Deparaffinization/Rehydration 1. Deparaffinize/hydrate sections: 2. Incubate sections in three washes of xylene for 5 min each. 3. Incubate sections in two washes of 100% ethanol for 10 min each. 4. Incubate sections in two washes of 95% ethanol for 10 min each. 5. Wash sections two times in dH2O for 5 min each. 6.Antigen retrieval: For Citrate: Heat slides in a microwave submersed in 1X citrate unmasking solution until boiling is initiated; continue with 10 min at a sub-boiling temperature (95°-98°C). Cool slides on bench top for 30 min. Staining 1. Wash sections in dH2O three times for 5 min each. 2. Incubate sections in 3% hydrogen peroxide for 10 min. 3. Wash sections in dH2O two times for 5 min each. 4. Wash sections in wash buffer for 5 min. 5. Block each section with 100–400 µl of blocking solution for 1 hr at room temperature. 6. Remove blocking solution and add 100–400 µl primary antibody diluent in to each section. Incubate overnight at 4°C. 7. Remove antibody solution and wash sections with wash buffer three times for 5 min each. 8. Cover section with 1–3 drops HRPas needed. Incubate in a humidified chamber for 30 min at room temperature. 9. Wash sections three times with wash buffer for 5 min each. 10. Add DAB Chromogen Concentrate to DAB Diluent and mix well before use. 11. Apply 100–400 µl DAB to each section and monitor closely. 1–10 min generally provides an acceptable staining intensity. 12. Immerse slides in dH2O. 13. If desired, counterstain sections with hematoxylin. 14. Wash sections in dH2O two times for 5 min each. 15. Dehydrate sections: Incubate sections in 95% ethanol two times for 10 sec each; Repeat in 100% ethanol, incubating sections two times for 10 sec each; Repeat in xylene, incubating sections two times for 10 sec each. 16. Mount sections with coverslips and mounting medium.

IHC

Experimental Protocol：

Deparaffinization/Rehydration

1. Deparaffinize/hydrate sections:

2. Incubate sections in three washes of xylene for 5 min each.

3. Incubate sections in two washes of 100% ethanol for 10 min each.

4. Incubate sections in two washes of 95% ethanol for 10 min each.

5. Wash sections two times in dH2O for 5 min each.

6.Antigen retrieval: For Citrate: Heat slides in a microwave submersed in 1X citrate unmasking solution until boiling is initiated; continue with 10 min at a sub-boiling temperature (95°-98°C). Cool slides on bench top for 30 min.

Staining

1. Wash sections in dH2O three times for 5 min each.

2. Incubate sections in 3% hydrogen peroxide for 10 min.

3. Wash sections in dH2O two times for 5 min each.

4. Wash sections in wash buffer for 5 min.

5. Block each section with 100–400 µl of blocking solution for 1 hr at room temperature.

6. Remove blocking solution and add 100–400 µl primary antibody diluent in to each section. Incubate overnight at 4°C.

7. Remove antibody solution and wash sections with wash buffer three times for 5 min each.

8. Cover section with 1–3 drops HRPas needed. Incubate in a humidified chamber for 30 min at room temperature.

9. Wash sections three times with wash buffer for 5 min each.

10. Add DAB Chromogen Concentrate to DAB Diluent and mix well before use.

11. Apply 100–400 µl DAB to each section and monitor closely. 1–10 min generally provides an acceptable staining intensity.

12. Immerse slides in dH2O.

13. If desired, counterstain sections with hematoxylin.

14. Wash sections in dH2O two times for 5 min each.

15. Dehydrate sections: Incubate sections in 95% ethanol two times for 10 sec each; Repeat in 100% ethanol, incubating sections two times for 10 sec each; Repeat in xylene, incubating sections two times for 10 sec each.

16. Mount sections with coverslips and mounting medium.

Datasheet & SDS

生物学的記述

Specificity
Pancreatic Polypeptide Antibody (Rabbit mAb) [L20N2] detects endogenous levels of total Pancreatic Polypeptide protein.

タンパク質の局在
細胞外環境

Uniprot ID
P01298

Clone
L20N2

Synonym(s)
PNP, PPY, Pancreatic polypeptide prohormone, PH, Pancreatic polypeptide Y, PNP, PPY, Pancreatic polypeptide, Pancreatic polypeptide Y, Pancreatic prohormone, prepro-PP (prepropancreatic polypeptide)

Background
Pancreatic polypeptide (PP) is a 36–amino acid member of the neuropeptide Y (NPY) family that is synthesized and stored in PP (F) cells of the endocrine pancreas, predominantly in the ventral head region, and released into the circulation in response to nutrient stimulation and vagal cholinergic input as a systemic regulator of digestive function and energy homeostasis. The peptide adopts the characteristic PP‑fold, a compact polyproline II helix followed by an α‑helix, which presents key side chains for high‑affinity binding to Y4 receptors and lower‑affinity engagement of Y5 and, in some species, Y6 receptors, enabling selective activation of G protein–coupled receptor signaling in the brainstem, hypothalamus, and pancreatic islets. Secretion follows a biphasic pattern after a meal, with an early vagally mediated component and a later intestinal phase driven by cholecystokinin and other gut hormones; cholinergic vagal stimulation is the dominant driver of PP release and acts as an obligatory conduit for many other secretagogues, making PP a sensitive readout of vagal tone and autonomic regulation of the endocrine pancreas. Circulating PP feeds back on the exocrine pancreas, where it inhibits secretion of fluid, bicarbonate, and digestive enzymes and counteracts cholecystokinin‑induced pancreatic secretion, and on the biliary tract and stomach, where it reduces gallbladder contraction and alters gastric emptying, thereby coordinating postprandial digestive efficiency and limiting excessive pancreatic output. At the level of central energy balance, PP acting via Y4 receptors on vagal afferents and hypothalamic nuclei, including the arcuate, ventromedial, and lateral hypothalamus, suppresses food intake, decreases orexin expression in the lateral hypothalamic “feeding center,” and increases brain‑derived neurotrophic factor expression in the ventromedial “satiety center,” resulting in a net anorexigenic effect that reduces body weight and adiposity in animal models with exogenous PP administration or PP overexpression. PP also signals directly to pancreatic islets, where Y4/Y1‑family receptors on α cells mediate an inhibitory effect on glucagon secretion, linking postprandial PP rises to modulation of hepatic glucose output and contributing to fine‑tuning of glucose homeostasis alongside insulin and somatostatin. Low PP responses are associated with vagal dysfunction and chronic pancreatitis, and markedly elevated PP levels with PP‑secreting neuroendocrine tumors, while pharmacological or supraphysiological PP infusion in humans alters satiety, gastric accommodation, and food tolerance, underscoring its potential as a tool to probe gut–brain signaling and as a candidate target for anti‑obesity and metabolic therapies.

Background

Pancreatic polypeptide (PP) is a 36–amino acid member of the neuropeptide Y (NPY) family that is synthesized and stored in PP (F) cells of the endocrine pancreas, predominantly in the ventral head region, and released into the circulation in response to nutrient stimulation and vagal cholinergic input as a systemic regulator of digestive function and energy homeostasis. The peptide adopts the characteristic PP‑fold, a compact polyproline II helix followed by an α‑helix, which presents key side chains for high‑affinity binding to Y4 receptors and lower‑affinity engagement of Y5 and, in some species, Y6 receptors, enabling selective activation of G protein–coupled receptor signaling in the brainstem, hypothalamus, and pancreatic islets. Secretion follows a biphasic pattern after a meal, with an early vagally mediated component and a later intestinal phase driven by cholecystokinin and other gut hormones; cholinergic vagal stimulation is the dominant driver of PP release and acts as an obligatory conduit for many other secretagogues, making PP a sensitive readout of vagal tone and autonomic regulation of the endocrine pancreas. Circulating PP feeds back on the exocrine pancreas, where it inhibits secretion of fluid, bicarbonate, and digestive enzymes and counteracts cholecystokinin‑induced pancreatic secretion, and on the biliary tract and stomach, where it reduces gallbladder contraction and alters gastric emptying, thereby coordinating postprandial digestive efficiency and limiting excessive pancreatic output. At the level of central energy balance, PP acting via Y4 receptors on vagal afferents and hypothalamic nuclei, including the arcuate, ventromedial, and lateral hypothalamus, suppresses food intake, decreases orexin expression in the lateral hypothalamic “feeding center,” and increases brain‑derived neurotrophic factor expression in the ventromedial “satiety center,” resulting in a net anorexigenic effect that reduces body weight and adiposity in animal models with exogenous PP administration or PP overexpression. PP also signals directly to pancreatic islets, where Y4/Y1‑family receptors on α cells mediate an inhibitory effect on glucagon secretion, linking postprandial PP rises to modulation of hepatic glucose output and contributing to fine‑tuning of glucose homeostasis alongside insulin and somatostatin. Low PP responses are associated with vagal dysfunction and chronic pancreatitis, and markedly elevated PP levels with PP‑secreting neuroendocrine tumors, while pharmacological or supraphysiological PP infusion in humans alters satiety, gastric accommodation, and food tolerance, underscoring its potential as a tool to probe gut–brain signaling and as a candidate target for anti‑obesity and metabolic therapies.

References
[1] Lonovics J, et al. Arch Surg. 1981 Oct;116(10):1256-64. [2] Khandekar N, et al. Mol Cell Endocrinol. 2015 Dec 15;418 Pt 1:33-41.

PVDFメンブレン孔径参考表

Protein Size (kDa)	PVDF Transfer Membrane Pore Size (μm)
< 10	0.22
10-20	0.22
20-30	0.45
30-45	0.45
45-70	0.45
80-100	0.45
100-140	0.45
> 140	0.45

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

* 必須

* 大学・企業名 大学・企業名を記入してください

* 名前 名前を記入してください

* 電子メール 電子メール・アドレスを記入してください 有効なメールアドレスを入力してください

電話番号

* 内容 お問い合わせ内容をご入力ください

Protein Size (kDa)	Separating Gel Percentage
4-40	20%
12-45	15%
10-70	12.5%
15-100	10%
25-100	8%
60-210	5%